👨‍💼 CUSTOMER CARE NO +918468865271

⭐ TOP RATED SELLER ON AMAZON, FLIPKART, EBAY & WALMART

🏆 TRUSTED FOR 10+ YEARS

  • From India to the World — Discover Our Global Stores

🚚 Extra 10% + Free Shipping? Yes, Please!

Shop above ₹5000 and save 10% instantly—on us!

THANKYOU10

Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease (Contemporary Cardiology)

Sale price Rs.10,119.00 Regular price Rs.18,399.00
Tax included


Genuine Products Guarantee

We guarantee 100% genuine products, and if proven otherwise, we will compensate you with 10 times the product's cost.

Delivery and Shipping

Products are generally ready for dispatch within 1 day and typically reach you in 3 to 5 days.

Get 100% refund on non-delivery or defects

On Prepaid Orders

Author: Lincoff, A. Michael

Brand: Humana

Edition: 2nd ed. 2003

Binding: hardcover

Format: Illustrated

Number Of Pages: 476

Release Date: 07-03-2003

Part Number: 4274033

Details: One of the most important developments in the field of cardiovascular medicine over the last two decades has been recognition of the key role played by arterial thrombosis in the pathogenesis of acute coronary syndromes, ischemic complications of percutane- ous coronary revascularization, and coronary and peripheral atherosclerosis. The phar- macologic armamentarium directed against vascular thrombosis has thus expanded substantially during that time, with development of new fibrinolytic agents, low-molecu- lar-weight heparins, direct thrombin inhibitors, antagonists to platelet activation, and the platelet glycoprotein lIb/IlIa inhibitors. Though clinical investigations of these com- pounds have been marked by failures as well as successes, there is little doubt that enhanced antithrombotic therapies have markedly improved the outcome of patients undergoing coronary revascularization or with acute coronary syndromes. Glycoprotein IIblIlIa receptor antagonists were introduced into clinical practice to overcome the limitations of approaches that inhibit only individual pathways of platelet activation. Multiple mechanisms of platelet activation in response to different agonists converge on the platelet membrane glycoprotein IIblIlIa complex, the "final common pathway" of platelet aggregation. The clinical hemorrhagic syndrome caused by a rare inherited defect in this receptor (Glanzmann' s thrombasthenia), characterized by muco- cutaneous and postsurgical bleeding, but infrequent spontaneous organ (particularly central nervous system) bleeding, suggested that therapeutic inhibition of this receptor might be a potent, yet well-tolerated means of treating thrombotic disorders.

EAN: 9781588291851

Package Dimensions: 10.0 x 7.2 x 1.3 inches

Languages: English